https://t.co/FXEwLqWC3S

S5-26.5 – 𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗕𝗮𝗰𝗸 𝗮𝘁 #𝗧𝗟𝗠𝟮𝟬𝟮𝟰: Promoting Healthy Livers and Looking Ahead to 2025 This final conversation focuses on conference presentations on Determinants of MASH Health and the Healthy Livers, Healthy Lives program, and what panelists anticipate for

S5-26.4 – 𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗕𝗮𝗰𝗸 𝗮𝘁 #𝗧𝗟𝗠𝟮𝟬𝟮𝟰: Patient Advocacy and Patient-Centric Trials This conversation covers the likely role of FGF-21 agents in future MASH therapy and discusses positive messages from the "FDA Corner" session. https://t.co/kVeOP7Muln #TLM2024

S5-26.3 – 𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗕𝗮𝗰𝗸 𝗮𝘁 #𝗧𝗟𝗠𝟮𝟬𝟮𝟰: FGF-21 Agents and the FDA Corner This conversation covers the likely role of FGF-21 agents in future MASH therapy and discusses positive messages from the "FDA Corner" session. https://t.co/ifVo9zV3Fp #TLM2024 #FGF21 #FDA

S5-26.2 - 𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗕𝗮𝗰𝗸 𝗮𝘁 #𝗧𝗟𝗠𝟮𝟬𝟮𝟰: Patient Genotyping and MASH Clusters https://t.co/PKdKyYE6y3 This conversation starts by asking whether approval of two drugs for use without biopsy will challenge MASH trial recruitment and goes on to look at recent

S5-26.1 - 𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗕𝗮𝗰𝗸 𝗮𝘁 #𝗧𝗟𝗠𝟮𝟬𝟮𝟰: Semaglutide Passes the ESSENCE Test https://t.co/2yqScCudKA In the first conversation of our review of #TLM2024, panelists share general impressions and discuss the ESSENCE trial, semaglutide's Phase 3 trial demonstrating

𝗦𝘂𝗿𝗳’𝘀 𝗨𝗽: 𝗦𝗲𝗮𝘀𝗼𝗻 𝟱 𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝟮𝟲 𝗜𝘀 𝗡𝗼𝘄 𝗢𝗻𝗹𝗶𝗻𝗲❗ A diverse group of MASLD/MASH stakeholders joins Jörn Schattenberg and Roger Green to discuss The Liver Meeting 2024 about key breakthroughs, explore emerging research on new therapies, and reflect

Exciting News Ahead: A New Wave of Surfing the MASH Tsunami Hey, it's Roger Green, executive producer and host of the Surfing the MASH Tsunami podcast. We've been gone for a couple of months, but we'll be back over the next few weeks. We'll have an episode on Australia, one on

I mean… come on… the takes Surfing to a whole new level! Let's go!!!! #SurifngMASH

𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻 𝗼𝗳 𝗧𝗵𝗲 𝗪𝗲𝗲𝗸: “Which approach will more significantly impact resmetirom treatment: using NITs to identify Advanced NASH patients or continuing therapy until disease progression?” ANSWER HERE: https://t.co/6FBwmzzkom #surfingmash #QuestionOfTheWeek

S5-E25 - Reviewing Expert Recommendations on the Use of Resmetirom Maru Rinella @marurinella, corresponding author for the recent expert panel recommendations on resmetirom, joins the Surfers to discuss key points of the recommendations and the rationale behind them.

S5-24.5 - SurfingMASH Question of The Week: Keys to Improving Provider-Patient Communication S5 E23 panelists Mike Betel and José WIllemse join Roger Green to review the three answers audience members sent for Season 5 Episode 23's Question of the Week on Provider-Patient

S5 - E24.4 - EASL Congress Six Weeks Later: Jeff McIntyre's Key Implications for GLI In the second half of Roger Green's interview with @GlobalLiver Institute Vice President, Liver Programs Jeff McIntyre, Jeff discusses the implications of his key EASL Congress takeaways for GLI

S5-E24.3 - EASL Congress Six Weeks Later: Jeff McIntyre's Key Takeaways @GlobalLiver Institute Vice President of Liver Programs Jeff McIntyre joins Roger Green to discuss what he considers key takeaways for GLI from EASL Congress 2024. https://t.co/Dc0MBObFHk #EASLCongress

S5-E24.2 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Implications @PharmaNestInc Founder and CEO Mathieu Petitjean joins Roger Green to discuss key implications for his business from what he learned at EASL Congress 2024. https://t.co/aJUpZabXMS #EASLCongress

S5-E24.1 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Takeaways @PharmaNestInc Founder and CEO Mathieu Petitjean joins Roger Green to discuss key takeaways for his business from EASL Congress 2024. https://t.co/c1WKQWJUBe #EASLCongress #KeyTakeaways #PharmaNest